Compumedics Limited
AASX:CMP0.24
AUD
-0.01
(-4.00%)
ISIN
AU000000CMP2
Return %
Stock
S&P 500
1Y
-40.00
14.20
3Y
54.84
81.12
5Y
-38.46
68.34
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- David Burton
- Full Time Employees
- 175
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 30-40 Flockhart Street Abbotsford VIC Australia 3067
- IPO Date
- Dec 21, 2000
- Website
- compumedics.com.au
- Similar Companies
- Business
- Compumedics Limited Compumedics Limited engages in the development, manufacture, and commercialization of diagnostic technologies for sleep disorders, brain function including neurological research, and ultrasonic blood-flow monitoring applications. The company offers a comprehensive range of products including sleep diagnostics systems such as Somfit, Somté PSG, Grael PSG, Grael 4K PSG, Falcon PSG, Falcon HST, Siesta 802, and Okti; neurology solutions encompassing Profusion EEG software, Profusion neXus 360 web-based patient data management, CURRY signal processing, Nuevo LTM EEG, Orion LifeSpan MEG magnetoencephalography systems, and quick-cap EEG electrode arrays; ultrasonic Doppler diagnostics via its DWL brand; software platforms for scalable operations; and consumables, supplies, and accessories for diagnostic and research use. Compumedics Limited serves sleep clinics, neurology departments, hospitals, pharmaceutical clinical trials, and research institutions targeting patients with sleep apnea, neurological disorders, epilepsy, and vascular conditions. The company operates geographically across the Americas through its US-based Neuroscan subsidiary in Charlotte, North Carolina; Australia and Asia Pacific with significant presence in China, South Korea, and other regions; and Europe and the Middle East via its Germany-based DWL Elektronische GmbH operations in Singen, Dresden, Freiberg, and France in Strasbourg; with global headquarters in Abbotsford, Victoria, Australia. Founded in 1987 by Executive Chairman Dr. David Burton, who designed Australia's first fully computerized sleep clinic, the company listed on the Australian Securities Exchange in 2000 as ASX: CMP and maintains a subsidiary structure without a listed parent. Recent developments include signing two four-year distribution agreements in China in July 2025 valued at A$24.4 million with long-term partners, featuring minimum 10% annual growth commitments for sleep diagnostics in Northern China and sleep/neurology in Eastern China; achieving record FY2025 orders of A$63.4 million, revenues of A$51.0 million, and EBITDA of A$2.9 million driven by SaaS growth; securing a fifth MEG sale of A$4.9 million in November 2025 fueled by China demand; FDA clearance for single-use SomfitD expanding the US market; multiple Somfit sales to pharmaceutical contract research organizations including a US$1 million deal; board renewal with the appointment of Christopher R. Barys, former Johnson & Johnson executive, in September 2025; and ongoing magnetoencephalography installations such as at Tianjin Normal University in China.